Journey Medical Corp
NASDAQ:DERM

Watchlist Manager
Journey Medical Corp Logo
Journey Medical Corp
NASDAQ:DERM
Watchlist
Price: 4.49 USD -1.32%
Market Cap: 89.8m USD
Have any thoughts about
Journey Medical Corp?
Write Note

Net Margin
Journey Medical Corp

-31.7%
Current
-38%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-31.7%
=
Net Income
-18.3m
/
Revenue
57.8m

Net Margin Across Competitors

Country US
Market Cap 94.7m USD
Net Margin
-32%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.2B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 350.6B USD
Net Margin
17%
Country US
Market Cap 252B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Journey Medical Corp
Glance View

Market Cap
93.1m USD
Industry
Pharmaceuticals

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.

DERM Intrinsic Value
4.79 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-31.7%
=
Net Income
-18.3m
/
Revenue
57.8m
What is the Net Margin of Journey Medical Corp?

Based on Journey Medical Corp's most recent financial statements, the company has Net Margin of -31.7%.